WO2003000851A3 - Method for rapid screening of bacterial transformants and novel simian adenovirus proteins - Google Patents

Method for rapid screening of bacterial transformants and novel simian adenovirus proteins Download PDF

Info

Publication number
WO2003000851A3
WO2003000851A3 PCT/US2002/019735 US0219735W WO03000851A3 WO 2003000851 A3 WO2003000851 A3 WO 2003000851A3 US 0219735 W US0219735 W US 0219735W WO 03000851 A3 WO03000851 A3 WO 03000851A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
rapid screening
simian adenovirus
adenovirus proteins
bacterial transformants
Prior art date
Application number
PCT/US2002/019735
Other languages
French (fr)
Other versions
WO2003000851A2 (en
Inventor
Guangping Gao
James M Wilson
Original Assignee
Univ Pennsylvania
Guangping Gao
James M Wilson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Guangping Gao, James M Wilson filed Critical Univ Pennsylvania
Priority to ES02756264T priority Critical patent/ES2375557T3/en
Priority to AU2002322285A priority patent/AU2002322285A1/en
Priority to AT02756264T priority patent/ATE530672T1/en
Priority to US10/477,527 priority patent/US7344872B2/en
Priority to JP2003507238A priority patent/JP4399255B2/en
Priority to EP02756264A priority patent/EP1409748B1/en
Priority to CA2450470A priority patent/CA2450470C/en
Publication of WO2003000851A2 publication Critical patent/WO2003000851A2/en
Publication of WO2003000851A3 publication Critical patent/WO2003000851A3/en
Priority to US12/011,377 priority patent/US7838277B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

Chimpanzee serotype C68 proteins, peptides, and polypeptide are provided. Also provided are novel adenoviruses derived from these proteins, as well as compositions containing these proteins and methods of using same for immunization and therapy. Further, a rapid method for screening recombinant transformants using a visually detectable method is described.
PCT/US2002/019735 2001-06-22 2002-06-20 Method for rapid screening of bacterial transformants and novel simian adenovirus proteins WO2003000851A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
ES02756264T ES2375557T3 (en) 2001-06-22 2002-06-20 ADENOVIRUS RECOMBINANTS THAT UNDERSTAND PROTEIN OF ADEOVIRUS OF AIMS AND USES OF THE SAME.
AU2002322285A AU2002322285A1 (en) 2001-06-22 2002-06-20 Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
AT02756264T ATE530672T1 (en) 2001-06-22 2002-06-20 RECOMBINANT ADENOVIRUSES WITH MONKEY ADENOVIRUS PROTEINS AND USE THEREOF.
US10/477,527 US7344872B2 (en) 2001-06-22 2002-06-20 Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
JP2003507238A JP4399255B2 (en) 2001-06-22 2002-06-20 A method for rapid selection of bacterial transformants and a novel simian adenovirus protein
EP02756264A EP1409748B1 (en) 2001-06-22 2002-06-20 Recombinant Adenoviruses comprising simian adenovirus proteins and uses thereof.
CA2450470A CA2450470C (en) 2001-06-22 2002-06-20 Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
US12/011,377 US7838277B2 (en) 2001-06-22 2008-01-25 Method for rapid screening of bacterial transformants and novel simian adenovirus proteins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30050101P 2001-06-22 2001-06-22
US60/300,501 2001-06-22
US38563202P 2002-06-04 2002-06-04
US60/385,632 2002-06-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10477527 A-371-Of-International 2002-06-20
US12/011,377 Division US7838277B2 (en) 2001-06-22 2008-01-25 Method for rapid screening of bacterial transformants and novel simian adenovirus proteins

Publications (2)

Publication Number Publication Date
WO2003000851A2 WO2003000851A2 (en) 2003-01-03
WO2003000851A3 true WO2003000851A3 (en) 2003-02-20

Family

ID=26971814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/019735 WO2003000851A2 (en) 2001-06-22 2002-06-20 Method for rapid screening of bacterial transformants and novel simian adenovirus proteins

Country Status (8)

Country Link
US (2) US7344872B2 (en)
EP (1) EP1409748B1 (en)
JP (1) JP4399255B2 (en)
AT (1) ATE530672T1 (en)
AU (1) AU2002322285A1 (en)
CA (1) CA2450470C (en)
ES (1) ES2375557T3 (en)
WO (1) WO2003000851A2 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3928858A1 (en) * 1989-08-31 1991-03-07 Beiersdorf Ag NETWORKED HYDROGELES AND METHOD FOR THE PRODUCTION THEREOF
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
CA2450470C (en) 2001-06-22 2012-08-28 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
CA2466431C (en) 2001-11-21 2014-08-05 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US7491508B2 (en) 2003-06-20 2009-02-17 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
AU2011247887B2 (en) * 2004-01-23 2014-11-20 Msd Italia S.R.L. Chimpanzee adenovirus vaccine carriers
LT2163260T (en) * 2004-01-23 2017-06-26 Msd Italia S.R.L. Chimpanzee adenovirus vaccine carriers
JP2008500364A (en) * 2004-05-25 2008-01-10 キメラコア， インコーポレイテッド Self-assembling nanoparticle drug delivery system
ATE492643T1 (en) * 2004-10-13 2011-01-15 Crucell Holland Bv IMPROVED ADENOVIRUS VECTORS AND THEIR USE
NZ581306A (en) 2004-11-16 2011-03-31 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
EP1893636A2 (en) 2005-06-17 2008-03-05 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus nucleic acid vaccine
AU2007348315A1 (en) * 2006-04-07 2008-09-12 Chimeros, Inc. Compositions and methods for treating B- cell malignancies
CA2683063A1 (en) * 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
KR101761683B1 (en) 2007-11-28 2017-07-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Simian subfamily b adenoviruses sadv-28,27,-29,-32,-33, and -35 and uses thereof
EP2463362B1 (en) * 2007-11-28 2017-11-08 The Trustees Of The University Of Pennsylvania Simian subfamily c adenovirus SAdv-31 and uses thereof
PL2220241T3 (en) * 2007-11-28 2017-06-30 The Trustees Of The University Of Pennsylvania Adenovirus comprising a Simian E Adenovirus SAdV-39 capsid hexon protein and uses thereof
EP2250255A2 (en) 2008-03-04 2010-11-17 The Trustees of the University of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
JP5809978B2 (en) * 2008-10-31 2015-11-11 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Simian adenovirus SAdV-43, -45, -46, -47, -48, -49 and -50 and their uses
DK2391638T3 (en) * 2009-02-02 2018-08-27 Glaxosmithkline Biologicals Sa Abeadenovirus nucleic acid and amino acid sequences, vectors containing them, and uses thereof.
SG172935A1 (en) 2009-02-02 2011-08-29 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
CA2762203A1 (en) 2009-05-29 2010-12-02 Soumitra Roy Simian adenovirus 41 and uses thereof
WO2011133890A1 (en) 2010-04-23 2011-10-27 University Of Massachusetts Cns targeting aav vectors and methods of use thereof
CA2833905C (en) 2010-04-23 2019-09-10 University Of Massachusetts Multicistronic expression constructs
JP2013533847A (en) 2010-04-23 2013-08-29 ユニバーシティ オブ マサチューセッツ AAV-based treatment of cholesterol-related disorders
CN103118702A (en) 2010-09-20 2013-05-22 克鲁塞尔荷兰公司 Therapeutic vaccination against active tuberculosis
WO2012071318A2 (en) 2010-11-23 2012-05-31 The Trustees Of The University Of Pennsylvania Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof
JP2014527072A (en) 2011-09-09 2014-10-09 バイオメド リアルティー， エル．ピー． Methods and compositions for controlling the assembly of viral proteins
MX358019B (en) 2012-05-18 2018-08-02 Univ Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof.
KR102089121B1 (en) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 Oncolytic adenovirus compositions
BR112016008806A2 (en) 2013-11-01 2017-10-03 Pfizer VECTORS FOR EXPRESSION OF PROSTATE-ASSOCIATED ANTIGENS
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
CN107073051B (en) 2014-10-21 2021-08-24 马萨诸塞大学 Recombinant AAV variants and uses thereof
JP6401871B2 (en) 2014-11-05 2018-10-10 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． AADC polynucleotide for the treatment of Parkinson's disease
SG11201703419UA (en) 2014-11-14 2017-05-30 Voyager Therapeutics Inc Modulatory polynucleotides
EP3218484A4 (en) 2014-11-14 2018-05-30 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
US10983110B2 (en) 2015-12-02 2021-04-20 Voyager Therapeutics, Inc. Assays for the detection of AAV neutralizing antibodies
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
KR20220163505A (en) 2016-02-23 2022-12-09 솔크 인스티튜트 포 바이올로지칼 스터디즈 Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3458588A4 (en) 2016-05-18 2020-01-15 Voyager Therapeutics, Inc. Modulatory polynucleotides
WO2017201258A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
WO2018035388A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
US20200283743A1 (en) 2016-08-17 2020-09-10 The Broad Institute, Inc. Novel crispr enzymes and systems
EP3831281A1 (en) 2016-08-30 2021-06-09 The Regents of The University of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
AU2017341849B2 (en) 2016-10-13 2024-03-21 University Of Massachusetts AAV capsid designs
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
US20200405639A1 (en) 2017-04-14 2020-12-31 The Broad Institute, Inc. Novel delivery of large payloads
JP2020518258A (en) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Amyotrophic lateral sclerosis (ALS) treatment composition and method
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
TW202333779A (en) 2017-05-08 2023-09-01 美商磨石生物公司 Alphavirus neoantigen vectors
JOP20190269A1 (en) 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
US11497576B2 (en) 2017-07-17 2022-11-15 Voyager Therapeutics, Inc. Trajectory array guide system
EP3808849A1 (en) 2017-08-03 2021-04-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
AU2018352236A1 (en) 2017-10-16 2020-04-23 The Curators Of The University Of Missouri Treatment of amyotrophic lateral sclerosis (ALS)
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
US20220153871A1 (en) 2018-01-04 2022-05-19 Iconic Therapeutics, Inc. Anti-Tissue Factor Antibodies, Antibody-Drug Conjugates, and Related Methods
EP3807404A1 (en) 2018-06-13 2021-04-21 Voyager Therapeutics, Inc. Engineered 5' untranslated regions (5' utr) for aav production
EP3826719A1 (en) 2018-07-24 2021-06-02 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
TW202035689A (en) 2018-10-04 2020-10-01 美商航海家醫療公司 Methods for measuring the titer and potency of viral vector particles
SG11202103425YA (en) 2018-10-05 2021-05-28 Voyager Therapeutics Inc Engineered nucleic acid constructs encoding aav production proteins
WO2020081490A1 (en) 2018-10-15 2020-04-23 Voyager Therapeutics, Inc. EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM
AU2019406778A1 (en) 2018-12-17 2021-07-22 Massachusetts Institute Of Technology Crispr-associated transposase systems and methods of use thereof
EP3917566A4 (en) 2019-01-31 2022-10-26 Oregon Health & Science University Methods for using transcription-dependent directed evolution of aav capsids
US20220220469A1 (en) 2019-05-20 2022-07-14 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
BR122024002387A2 (en) 2019-05-30 2024-03-12 Gritstone Bio, Inc. ADENOVIRUS VECTORS, PHARMACEUTICAL COMPOSITION, ISOLATED NUCLEOTIDE SEQUENCE, ISOLATED CELL, VECTOR, KIT, USES OF A VECTOR, METHOD FOR MAKING THE VECTOR, METHODS FOR PRODUCING A VIRUS AND VIRAL VECTOR
AU2021320896A1 (en) 2020-08-06 2023-03-23 Gritstone Bio, Inc. Multiepitope vaccine cassettes
BR112023015303A2 (en) 2021-02-01 2023-11-14 Regenxbio Inc METHOD TO TREAT CLN2 DISEASE DUE TO TPP1 DEFICIENCY IN A SUBJECT
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083716A (en) * 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
CA2321135A1 (en) 1998-02-17 1999-08-19 Uab Research Foundation Modified adenovirus containing a fiber replacement protein
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CA2450470C (en) 2001-06-22 2012-08-28 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
US20030092161A1 (en) * 2001-09-19 2003-05-15 The Trustees Of The University Of Pennsylvania Compositions and methods for production of recombinant viruses, and uses therefor
CA2466431C (en) 2001-11-21 2014-08-05 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
US7291498B2 (en) * 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US7491508B2 (en) * 2003-06-20 2009-02-17 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
FR2860004A1 (en) 2003-09-18 2005-03-25 Roussy Inst Gustave Adenoviral vector encoding modified capsid protein, useful in gene therapy of e.g. cancer and cystic fibrosis, can infect cells deficient in, or lacking, the common receptor for Coxsackie virus B3 and adenovirus
DE602007004470D1 (en) * 2006-04-28 2010-03-11 Univ Pennsylvania MODIFIED ADENOVIRUS HEXON PROTEIN AND APPLICATIONS THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083716A (en) * 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors

Also Published As

Publication number Publication date
EP1409748B1 (en) 2011-10-26
US20040171807A1 (en) 2004-09-02
CA2450470C (en) 2012-08-28
JP4399255B2 (en) 2010-01-13
CA2450470A1 (en) 2003-01-03
US20080219954A1 (en) 2008-09-11
ES2375557T3 (en) 2012-03-02
JP2004537300A (en) 2004-12-16
WO2003000851A2 (en) 2003-01-03
EP1409748A4 (en) 2005-03-30
AU2002322285A1 (en) 2003-01-08
US7344872B2 (en) 2008-03-18
EP1409748A2 (en) 2004-04-21
US7838277B2 (en) 2010-11-23
ATE530672T1 (en) 2011-11-15

Similar Documents

Publication Publication Date Title
WO2003000851A3 (en) Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
WO1997033996A3 (en) Human bikunin
CA2277832A1 (en) Cyclic peptides that bind to urokinase-type plasminogen activator receptor
EP2258383A3 (en) Antigenic peptides derived from telomerase
EP1612272A3 (en) Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis
AU1873199A (en) Method of identifying binding site domains that retain the capacity of binding to an epitope
WO2001052875A8 (en) Vegf-d/vegf-c/vegf peptidomimetic inhibitor
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
CA2321177A1 (en) Recombinant fibronectin-based extracellular matrix for wound healing
NO960767L (en) Protocadherin proteins and their use
PT737207E (en) HUMAN PLASMA INHIBITORS DERIVED FROM KUNITZ DOMAINS
EP2110385A8 (en) Stabilized factor VIII with engineered disulfide bonds
AU4723596A (en) Method for preparing a recombinant adenovirus genome
WO2006131749A3 (en) Scaffold
DE69735207D1 (en) NOVEL, FIBRINOGENIC BINDING PROTEIN, DERIVED FROM A COAGULASE NEGATIVE STAPHYLOKOKKUS
AU2003222717A1 (en) Streptavidin-binding peptide
EP0783521B8 (en) Polypeptide compounds containing d-2-alkyltryptophan capable of promoting the release of growth hormone
WO2002092758A8 (en) Gastrokines and derived peptides including inhibitors
WO2000058465A3 (en) Flint polypeptide analogs
WO2000032745A3 (en) Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof
EP0643728A4 (en) Icam-related protein.
WO2002002148A3 (en) Dual recombinant gene therapy compositions and methods of use
EP0801133A3 (en) Hydroperoxide lyases
AU9629498A (en) Method for the production of (poly)peptides by using truncated variants of the sv40 large t antigen with an intact n terminus
CA2235471A1 (en) Dna encoding a plasminogen activating protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10477527

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2450470

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003507238

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002756264

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002756264

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642